Skip to main content
Caplight Logo









BioGenCell

BioGenCell

Private
NetanyaHealthcare & Life Scienceshttps://biogencell.net

Last Round

Seed

May 9, 2022

Total Funding Raised

$16M

Company Overview

BioGenCell operates in Healthcare & Life Sciences and is based in Netanya. Its latest recorded funding round was a Seed round in May 2022.

BioGenCell is a biotechnology company that develops personalized cell therapy treatments for degenerative microvascular diseases using its proprietary TRACT technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

BioGenCell Comparables

Compare BioGenCell with similar companies based on industry and business-model similarity.

BioGenCell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ixaka Ltd
84%
Hemostemix
84%
Lisata Therapeutics
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

BioGenCell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 9, 2022
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Yael Porat

Chief Executive Officer

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors grew 95% MoM, from 601 to 1.2K.

  • Jan 8, 2026

    Monthly visitors increased 83% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

BioGenCell Filings

Explore SEC and related filing metadata, where available.

BioGenCell filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about BioGenCell's valuation, stock price, and market status.

Is BioGenCell a public or private company?

BioGenCell is a private company.

What is the current stock price of BioGenCell?

BioGenCell is a private company, so its shares have no public market price. Caplight tracks BioGenCell's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is BioGenCell worth (valuation)?

Valuation information for BioGenCell is not publicly available.

Can I buy BioGenCell stock?

BioGenCell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was BioGenCell's last funding round?

BioGenCell's most recent funding round was Seed on May 9, 2022.

Who are the main investors in BioGenCell?

Investor information for BioGenCell is not publicly disclosed.

Will BioGenCell IPO soon?

No public IPO plans have been announced for BioGenCell.

How can I track BioGenCell secondary market activity?

Caplight tracks bids, offers, and trades in BioGenCell's shares on secondary markets.

Firmographic Details

HeadquartersNetanya
Employee Range12
Year Founded2008
Last FundingMay 9, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?